Drugs / EMD 521873
EMD 521873
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00879866 | Apr 2009 → Feb 2011 | non-small cell lung carcinoma | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 1 | NCT01032681 | Dec 2006 → Feb 2011 | non-Hodgkin lymphoma | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01973608 | Jan 2014 → Apr 2015 | melanoma | EMD Serono | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EMD 521873 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00879866 ↗ |
| Known as | MSB0010445 | “NHS-IL2 (selectikine, EMD 521873, MSB0010445) consists of human NHS76 (antibody specific for necrotic DNA) fused to genetically modified human interleukin 2 (IL-2)” PMID 25622640 ↗ Jan 2015 |
| Known as | NHS-IL2 | “NHS-IL2 (selectikine, EMD 521873, MSB0010445) consists of human NHS76 (antibody specific for necrotic DNA) fused to genetically modified human interleukin 2 (IL-2)” PMID 25622640 ↗ Jan 2015 |
| Known as | selectikine | “NHS-IL2 (selectikine, EMD 521873, MSB0010445) consists of human NHS76 (antibody specific for necrotic DNA) fused to genetically modified human interleukin 2 (IL-2)” PMID 25622640 ↗ Jan 2015 |
| Action | Activate | “selectively activates the high-affinity IL-2 receptor” PMID 25622640 ↗ Jan 2015 |
| Modality | Protein / enzyme biologic | “consists of human NHS76 (antibody specific for necrotic DNA) fused to genetically modified human interleukin 2 (IL-2)” PMID 25622640 ↗ Jan 2015 |
| Route | Intravenous | “Dose-escalated NHS-IL2 was administered as 1-h intravenous infusion” PMID 25622640 ↗ Jan 2015 |